Redcare Pharmacy Shares Plunge Amid Revised Profit Guidance

Redcare Pharmacy's stock fell 30% after slashing its margin forecast to 5%, overshadowing strong 2025 revenue growth of 24% driven by digital prescriptions.

Despite posting robust operational results for the 2025 fiscal year, Redcare Pharmacy has seen its stock price collapse as investors react to a significant downgrade in future profitability targets. The online pharmacy group's strong sales growth and customer acquisition have been overshadowed by concerns over mounting competitive pressures in key segments.

Investor Sentiment Sours on Strategic Shift

The market's reaction has been severe. Over a seven-day period, the share price plummeted by nearly 30 percent, closing at a new 52-week low of €42.22. This dramatic sell-off was triggered directly by management's updated strategic outlook, which presented a more conservative forecast for the coming years.

For the current 2026 business year, the company now anticipates revenue growth will slow to a range of 13 to 15 percent. More critically, Redcare Pharmacy has substantially reduced its medium-term margin target to just 5 percent. This revision highlights the intense competitive landscape the firm faces outside its core prescription drug business, particularly in the beauty and personal care categories. The margin compression in this non-prescription segment is expected to offset a portion of the structural profits generated by its rapidly expanding prescription service.

A Strong Operational Backdrop

The downward revision stands in stark contrast to the company's recently reported operational performance. For the full year 2025, Redcare Pharmacy delivered fundamentally solid results. Total revenue advanced by over 24 percent to reach €2.9 billion.

This growth was powered decisively by the prescription medication segment. In the German market alone, revenue from prescription drugs doubled to €503 million, underscoring the rapid adoption of the nation's digital prescription, or E-Rezept, system. The company also significantly expanded its user base, adding 1.4 million new active customers to bring its total to 13.9 million.

These scaling effects contributed to an improved adjusted operating profit (EBITDA), which rose to €57.4 million. Consequently, the EBITDA margin expanded from 1.4 percent to 2.0 percent. The company also managed to narrow its net loss, which was contained at €39.4 million.

The Path Forward: Balancing Growth and Profitability

Management's immediate challenge is now clear: to secure and improve profitability in areas beyond the digital prescription boom. While the company recently unveiled a detailed climate transition plan aimed at decarbonizing its entire supply chain, near-term financial performance will hinge on a more pressing operational issue.

The primary focus in upcoming quarters will be on how effectively the group can adapt its marketing expenditures and strategy to the shifting dynamics within the competitive cosmetics market. Success in this area is crucial for defending margins and achieving the newly stated financial targets. The market will be watching closely to see if Redcare Pharmacy can leverage its strong customer growth into sustainable profitability across all its business lines.